A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities

Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor

(2010) Raymond J. Andersen et al.   CANCER CELL

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant

(2010) Shihua Sun et al.   JOURNAL OF CLINICAL INVESTIGATION

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor

(2010) P. A. Watson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Integrated Genome Browser: free software for distribution and exploration of genome-scale datasets

(2009) J. W. Nicol et al.   BIOINFORMATICS

A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion-Resistant Growth

(2009) Z. Guo et al.   CANCER RESEARCH

Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer

(2009) K. E. Knudsen et al.   CLINICAL CANCER RESEARCH

Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer

(2009) Gerhardt Attard et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target

(2009) Yu Chen et al.   LANCET ONCOLOGY

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

(2009) C. Tran et al.   SCIENCE

Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications

(2008) Elahe A. Mostaghel et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance

(2008) S. M. Dehm et al.   CANCER RESEARCH

Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer

(2008) R. Hu et al.   CANCER RESEARCH

Targeting the androgen receptor pathway in prostate cancer

(2008) Yu Chen et al.   CURRENT OPINION IN PHARMACOLOGY

The T7-Primer Is a Source of Experimental Bias and Introduces Variability between Microarray Platforms

(2008) Ron M. Kerkhoven et al.   PLoS One

Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?

(2008) Emmanuel S Antonarakis et al.   Nature clinical practice. Oncology